ecancer

Editor's Choice for April 2017

Prof Gordon McVie - Editor in Chief, ecancer

28 Apr 2017

Novel bi-specific TCR-based reagents for targeted cancer immunotherapy

Dr Joseph Dukes - Immunocore Limited, Abingdon, UK

27 Apr 2017

Pembrolizumab and indoximod for melanoma

Prof Yousef Nabih Zakharia - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA

13 Apr 2017

Projections of cancer incidence and burden among the HIV-positive population in the United States through 2030

Jessica Yasmine Islam - University of North Carolina, Chapel Hill, USA

12 Apr 2017

Avelumab for metastatic Merkel cell carcinoma after chemotherapy

Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA

12 Apr 2017

Nivolumab and ipilimumab combination for advanced skin cancer

Dr James Larkin - The Royal Marsden, London, UK

12 Apr 2017

Checkmate 067 - combined nivolumab and ipilimumab

Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA

12 Apr 2017

Durable responses to avelumab in patients with Merkel cell carcinoma

Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA

12 Apr 2017

Understanding response and resistance to cancer therapy: Lessons learned from melanoma

Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston, USA

10 Apr 2017

Conference goals and cancer care in Brazil

Dr Carla Ismael - Presidente Sociedad Franco Brasilera de Oncología, Brasil

21 Dec 2016

Head and neck melanoma

Prof Carol Bradford - University of Michigan Medical School, Ann Arbor, USA

20 Dec 2016

Positive impact of specialised surgery in the fight against cancer

ESSO - SSO - BSSO

13 Dec 2016

More from ecancer